Journals / Viral Hepatitis Journal / 2016 / Cilt: 22 - Sayı: 3

İmmünsüpresif Tedavi ve Hepatit B Virüs Reaktivasyonu

Immunosuppressive Therapy and Hepatitis B Virus Reactivation

Pages
69–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antiviral drugs given after the initiation of immunosuppressive therapy are less effective for liver injury and should not be preferred.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Reactivation of hepatitis B virus (HBV) refers to reappearance of active necroinflammatory disease of the liver in an individual at an inactive hepatitis B surface antigen carrier state or who is known to have resolved HBV infection.
📊
Key Findings & Data:Patients receiving immunosuppressive therapy for malignant, autoimmune or chronic rheumatic diseases are at risk for HBV reactivation and a flare of their HBV infection due to loss of HBV immune control.
💡
Conclusion & Impact:Antiviral drugs given after the initiation of immunosuppressive therapy are less effective for liver injury and should not be preferred.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Reactivation of hepatitis B virus (HBV) refers to reappearance of active necroinflammatory disease of the liver in an individual at an inactive hepatitis B surface antigen carrier state or who is known to have resolved HBV infection. Patients receiving immunosuppressive therapy for malignant, autoimmune or chronic rheumatic diseases are at risk for HBV reactivation and a flare of their HBV infection due to loss of HBV immune control. HBV reactivation can be prevented by antiviral prophylaxis. Antiviral drugs given after the initiation of immunosuppressive therapy are less effective for liver injury and should not be preferred.

Özet

Hepatit B virüs (HBV) reaktivasyonu, inaktif hepatit B yüzey antijeni taşıyıcılarında veya iyileşmiş HBV enfeksiyonu olan kişilerde aktif nekroenflamatuvar karaciğer hastalığının yeniden ortaya çıkmasıdır. Malign, otoimmün ve romatizmal hastalıklarda kullanılan immünsupresif tedaviler, HBV immün baskılanmasının kaybına bağlı olarak HBV reaktivasyonu ve alevlenme için risk oluştururlar. HBV reaktivasyonu antiviral profilaksi ile önlenebilir. İmmünsüpresif tedaviye başlandıktan sonra verilen antiviral ilaçlar karaciğer hasarını önlemek için daha az etkili olup tercih edilmemelidir

🔖

Cite This Article

KÖKSAL, İ. (2016). İmmünsüpresif Tedavi ve Hepatit B Virüs Reaktivasyonu. Viral Hepatitis Journal, Cilt: 22 - Sayı: 3, 69–73. https://ajindex.com/articles/332837

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol. 2016;8:385-394.
  2. Lok ASF, Bonis PAL. Hepatitis B virus reactivation associated with immunosuppressive therapy. UpToDate. 2016. Zeuzem S. Patients at Risk for Hepatitis B Virus Reactivation. Hepatitis B Management in Special Populations. InPractice. 2016.
  3. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215-219.
  4. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology. 2016;63:261-283.
  5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2009;50:661-662. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.